Sera Prognostics Inc
Change company Symbol lookup
Select an option...
SERA Sera Prognostics Inc
CAC Camden National Corp
RE Everest Re Group Ltd
URRNF Twenty Seven Co Ltd
TWLV Twelve Seas Investment Co II
FLO Flowers Foods Inc
CAJ Canon Inc
WPC WP Carey Inc
PPT Putnam Premier Income Trust
GME GameStop Corp
Go

Health Care : Biotechnology |
Company profile

Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

Closing Price
$6.59
Day's Change
0.22 (3.45%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.94
Day's Low
5.75
Volume
(Below Average)
Volume:
43,980

10-day average volume:
54,204
43,980

Company Profile

Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.30x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

January 2022
Current Month
234.3K
Previous Month
190.1K
Percent of Float
0.90%
Days to Cover
4.7362 Days

Share Information

SERA is in a share class of common stock
Float
26.1M
Shares Outstanding
30.7M
Institutions Holding Shares
53
44.47%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Gregory C. CritchfieldChmn.
  • Jay M. MoyesCFO
  • Robert HarrisonCIO
  • Jay BonifaceCSO
  • Nadia F. Altomare

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.